三葉草生物－Ｂ (2197.HK)

0.320 -0.010 (-3.03%) 市場開市。 截至 11:03AM HKT。

三葉草生物－Ｂ

Park Place
49th Floor 1598-1601 West Nanjing Road Jing'an District
Shanghai
China
86 40 0883 3405
https://www.cloverbiopharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 387

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Peng Liang Ph.D.	Founder, Chief Scientific Officer & Chairman of the Board	4.96M	無	1961
Mr. Joshua G. Liang	CEO & Executive Director	8.8M	無	1993
Ms. Aileen Wang	Chief Financial Officer	無	無	1974
Dr. Yang Li Ph.D.	Chief Technology Officer	無	無	無
Ms. Lily Yang	Chief People Officer	無	無	無
Ms. Htay Htay Han MBBS	Chief Medical Officer of Vaccine	無	無	1969
Dr. Berry Michael Ph.D.	Chief Technical Operation Officer	無	無	1966
Ms. Abigail Bracha Ph.D.	Senior Vice President of Corporate Strategy & Business Development	無	無	無
Ms. Tracy Wang	Senior Vice President of Head of Regulatory Affairs, China	無	無	無
Dr. Nicholas Jackson M.Sc., Ph.D.	President of Global Research & Development	無	無	1971

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

公司管治

截至 無 止，三葉草生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。